Aktiespot

NGL Fine-Chem Limited (NGL FINE-CHEM LTD.) Aktie

NGLFINE.BO

₹2,662.10-69.50 (-2.54%)
Chart wird geladen...

NGL FINE-CHEM LTD.

Eröffnung2,720.95
Hoch2,743.45
Tief2,630.70
Volumen638
P/E35.09
Marktkapitalisierung16.45B
52-Wochen-Hoch3,000.00
52-Wochen-Tief985.05
Durchschn. Volumen1.01k
Dividende0.06%
Beta0.55
EPS75.87

Über NGL Fine-Chem Limited (NGL FINE-CHEM LTD.) Aktie

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Unternehmensinformationen

Börse: BSE (BSE)
Sektor: Sundhed
Branche: Lægemiddelproducenter – Generelt
Adresse:
301, E Square
400057 Mumbai, India
Telefon: + 91 22 4084 2222

Analystenempfehlungen

Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.

Niedrigstes Kursziel
Durchschnittliches Kursziel
Median Kursziel
Höchstes Kursziel

Andere sehen auch: